Anti-VEGFA antibody treatment suppresses proliferation of Tregs in the serum of the CT26 mouse CRC model, and this result was confirmed in peripheral blood from CRC patients treated with anti-human VEGFA antibody, bevacizumab, in clinic. Here, VEGFA is linked to colorectal carcinoma.